Here is what has occurred and what patients may expect in the coming months based on manufacturer announcements and regulatory filings: December 22, 2025: FDA approved oral Wegovy (semaglutide 25 mg), the first oral GLP-1 for weight loss
Monitor for recurrent hypoglycemic (low blood sugar) episodes using your CGM
Subsequent research has reinforced these concerning findings, with a Danish nationwide cohort study of 424,152 type 2 diabetes patients demonstrating that semaglutide doubled the five-year NAION risk compared to other treatments
Epididymitis typically results from retrograde pathogen ascent, most often bacterial [251, 252] although, non-infectious aetiologies such as vasculitis, autoimmune diseases, or medications (e.g., amiodarone) have been identified [253,254,255,256,257,258]
With approximately 6,000 employees and 15 production locations across the U.S